Chargement en cours...
Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
BACKGROUND: PD1 immune checkpoint blockade (αPD1 ICB) has shown unparalleled success in treating many types of cancer. However, response to treatment does not always lead to tumor rejection. While αPD1 ICB relies on cytotoxic CD8(+) T cells, antigen-presenting cells (APCs) at the tumor site are also...
Enregistré dans:
| Publié dans: | J Immunother Cancer |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Publishing Group
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7371367/ https://ncbi.nlm.nih.gov/pubmed/32690667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000588 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|